Related Experiment Video

Updated: Oct 11, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K

Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus

Ursula M Vogl1, Tomasz M Beer2, Ian D Davis3

  • 1Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.

European Journal of Cancer (Oxford, England : 1990)
|November 30, 2021
PubMed
Abstract

Insights

Expert consensus on advanced prostate cancer management is lacking in many areas, highlighting the need for more clinical trials to address evidence gaps and improve patient care.

Area of Science:

  • Oncology
  • Clinical Management
  • Evidence-Based Medicine

Background:

  • Despite advances in treatments and diagnostics for advanced prostate cancer, significant gaps in high-level evidence exist for clinical management.
  • The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 identified numerous areas lacking expert consensus.

Purpose of the Study:

  • To identify areas of non-consensus in advanced prostate cancer clinical management from the APCCC 2019.
  • To review ongoing phase III clinical trials addressing these non-consensus issues.
  • To highlight evidence gaps and guide future research priorities in advanced prostate cancer.

Main Methods:

  • An expert panel of 57 clinicians voted on 123 multiple-choice questions regarding advanced prostate cancer management.
  • Non-consensus was defined as <75% of panelists agreeing on an answer.
  • ClinicalTrials.gov was searched for relevant ongoing phase III trials in areas of non-consensus.

Main Results:

  • No consensus was reached on 88 (71.5%) of the clinical management questions.
  • Ongoing phase III trials were identified for some non-consensus issues.
  • Many non-consensus issues, including side effects of hormonal treatments, are not addressed by current phase III trials.

Conclusions:

  • The high percentage of non-consensus questions underscores significant gaps in evidence for advanced prostate cancer care.
  • Robust, clinically relevant trials are crucial to fill evidence gaps and establish high-level evidence.
  • This review identifies areas for future research and potential consensus in advanced prostate cancer management.
Keywords:
Advanced prostate cancerCastration-naïve prostate cancerCastration-resistant prostate cancerDecision-makingGeneticsHigh-risk localised prostate cancerHormone-sensitive prostate cancerImagingOligometastatic prostate cancerOverall survival

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.7K
Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts09:43

Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts

Published on: August 1, 2025

278

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
478
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
2.1K